Q-omics provides the consensus-scored PRR20G profile across patient tissues and cancer cell-line models. PRR20G expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PRR20G is differentially expressed in 8, with the highest sampling consensus in HNSC. Additionally, PRR20G RNA expression shows 9,410 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, HNSC, and TGCT as cancer lineages where PRR20G shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRR20G — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRR20G survival associations across molecular data types. PRR20G RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRR20G RNA expression–survival associations across cancer types. High PRR20G expression shows unfavorable associations in ACC, UVM, BRCA, PAAD and LIHC, but favorable associations in SKCM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PRR20G RNA expression.
This table summarizes PRR20G tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for PRR20G. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRR20G shows higher tumor expression in HNSC, KIRP, KIRC, LUSC, LIHC and COAD. The HNSC box plot shows higher PRR20G RNA expression in tumor versus normal tissue (log2 FC = +1.115, t-test p < 0.001).
This table shows molecular features associated with PRR20G in patient tissues and cancer cell lines. In patient samples, PRR20G shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, PRR20G RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia.
